FDA gives Cellectis a green light to relaunch off-the-shelf CAR-T studies — with several strings attached
Two months after the FDA forced Cellectis $CLLS to hit the brakes on a pair of clinical trials for their off-the-shelf CAR-T UCART123, regulators have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
